[Frontiers in Bioscience 15, 1164-1171, June 1, 2010]

dGirdin a new player of Akt /PKB signaling in Drosophila melanogaster

Masamitsu Yamaguchi1, Osamu Suyari1, Rika Nagai1, Masahide Takahashi2

1Department of Applied Biology, Insect Biomedical Research Center, Kyoto Institute of Technology, Sakyo-ku, Kyoto 606-8585, Japan, 2Department of Pathology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Aichi 466-8550, Japan

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. Girdin: its in vivo role as the Akt substrate
3.1. Identification of Girdin family proteins
3.2. Role of Akt in cell size control
3.3. Expression pattern of dGirdin PA and dGirdin PB
3.4. dGirdin is necessary for viability of Drosophila
3.5. dGirdin is required to control appropriate cell size in Drosophila wings
3.6. dGirdin is necessary for actin filament accumulation and may function downstream of the Akt
3.7. Role of Girdin in progression of human cancers
3.8. Drosophila models for tumor metastasis and angiogenesis
4. Summary and perspective
5. Acknowledgements
References

1. ABSTRACT

A novel substrate of Akt/PKB designated as Girdin (griders of actin filaments) has been identified in mammals and characterized as an actin-binding protein. A Girdin-like protein has been identified in Drosophila, which has two isoforms, dGirdin PA and dGirdin PB. Knockdown of dGirdin in the Drosophila wing imaginal disc cells resulted in reduction of cell size and this was enhanced by half reduction of the Akt gene dose. Furthermore the dGirdin-knockdown wing disc cells exhibited severe disruption of actin filaments. From these in vivo analyses, we conclude that dGirdin is required for actin organization and regulation of appropriate cell size under control of the Akt signaling pathway. Human Girdin plays important roles in cancer progression and angiogenesis. Therefore Girdin and its interacting proteins could be potential pharmaceutical targets for cancer therapies and tumor angiogenesis. Possible use of the Drosophila Girdin model in understanding the mechanisms of cancer progression and in developing preventive and therapeutic strategies will be discussed.

2. INTRODUCTION

Coordinate control of cell size, division and death plays important roles during development(1). In multicellular organisms, the control of cell size is necessary for dictating the proportions of organs, limb and the living entity(2). Cell size is regulated by a number of cellular signal molecules and one crucial example is the serine/threonine kinase Akt (also named Protein Kinase B, PKB). Akt is well known as the key regulator of many signal transduction pathways, modulating multiple processes including proliferation, growth, migration and cellular metabolism(3-6). Akt also negatively regulates apoptosis by phosphorylating and inactivating various components of the apoptotic machinery(7). Akt has a wide range of its substrates involved in the various cellular processes(8). A novel substrate of Akt designated as Girdin (griders of actin filaments) has been first identified in mammals(9). Recently we have identified a Girdin-like protein in Drosophila (dGirdin) (10). In this review, we summarize the roles of dGirdin in comparison with those of its mammalian counterparts, with a particular emphasis on its role on cell size control. We also focus on the emerging roles of human Girdin in cancer progression(11-13). A wealth of information on Drosophila development and genetics, and the existence of a number of mutants and transgenic lines, may significantly facilitate use of the Drosophila model in deciphering the mechanisms of cancer progression and in developing preventive and therapeutic strategies.

3. GIRDIN: ITS IN VIVO ROLES AS THE AKT SUBSTRATE

3. 1. Identification of Girdin family proteins

Mammalian Girdin has been identified as a novel protein that interacts with Akt(9, 14), the trimeric G protein Gi/s(15) and dynamin(16), a large GTPase necessary for endocytosis(17). Human and mouse Girdin genes encode proteins of 1,870 and 1,845 amino acids, respectively (Figure 1). Girdin carries -helical coiled-coil domain that spans more than two-thirds of the protein in its middle domain (the coiled-coil domain). The N-terminal domain (253 amino acids) shows significant homology to the microtubule-binding domain identified in the Hook family of proteins that link organelles to microtubules(16). Both of these domains contribute to the oligomerization of Girdin. Genome database analyses revealed Girdin paralogues, Daple (Dishevelled-associating protein with a high frequency of leucine residues) and FLJ00354, in the human and mouse genomes. It is known that Daple is a binding partner and regulator of Dishevelled, an important cytoplasmic component of the Wnt signaling pathway(18). Drosophila genome contains a single Girdin-like gene, CG12734 that encodes two proteins of 1,381 and 1,235 amino acids possibly produced by alternative splicing at the 3' region. These proteins were named dGirdin PA and dGirdin PB, respectively. The N-terminal and the coiled-coil domains between human and Drosophila Girdin show high homology, approximately 82% and 74 % similarity, respectively (Figure 1). Akt phosphorylates human Girdin at Ser-1417(9). The Akt phosphorylation site-like amino acid sequences are also conserved in dGirdin at similar amino acid position of human Girdin(10).

3. 2. Role of Akt in cell size control

Akt activity is principally determined by the level of phosphatidylinositol-3,4,5-triphosphate (PIP3) in the plasma membrane. Upon stimulation of receptor tyrosine kinase by growth factor stimulation, PIP3 is generated by the phosphatidylinositol-3-kinase (PI3K), which itself is counteracted by the lipid phosphatase, PTEN(19). When PIP3 levels are elevated, Akt is recruited to the plasma membrane and phosphorylated. Expression of Akt in Drosophila and mammalian tissues results in marked increase in cell growth/size and Akt signaling has been shown to regulate cell growth via the Tsc/Rheb/TOR (target of rapamycin) pathway(19). Signaling from Akt disrupts the Tsc complex, activating Rheb and consequently activating TOR, which directly stimulates ribosomal protein p70 S6 kinase (S6K) and thus stimulates translation of mRNAs encoding ribosomal proteins(20, 21). In fact Drosophila deficient in the S6 kinase gene (dS6K) exhibited extreme delay in development and severe reduction in body size(2). Thus, the control of cell size by the PI3K/Akt pathway has been in part explained by its ability to regulate protein synthesis by TOR, ribosomal protein p70 S6 kinase, and eukaryotic initiation factor 4E-binding protein-1 (eIF4E-BP1)/ PHAS-I(22-24). However, cell growth or increase in cell size also depends on enlargement of the actin cytoskeleton architecture and the control of actin organization by Akt/PI3K pathway is still poorly understood.

3. 3. Expression pattern of dGirdin PA and dGirdin PB

Both dGirdin PA and dGirdin PB are expressed in various tissues including wing imaginal discs throughout all developmental stages of Drosophila(10). The levels of dGirdin PA are high in unfertilized eggs and embryos. Maximum levels were observed in 6- to 12-h embryos with subsequent remarkable decrease before entering the larval stage. dGirdin PA levels then decreased slightly across the adult stage(10). Enrichment of dGirdin PA mRNA in adult ovary and tubules are also described in the database (FlyAtlas, http://flyatlas.org/). In contrast, dGirdin PB levels decreased in the early stage of embryogenesis and were then slightly increased in 12- to 18-h embryos, thereafter decreasing in a manner similar to dGirdin PA(10). The high levels of dGirdin PA and dGirdin PB in unfertilized eggs indicate maternal expression. The results also suggest that dGirdin PA might play more important roles than dGirdin PB during embryogenesis.

Mammalian Girdin is also expressed in virtually all tissues and in various cell lines(13). However in mouse embryonic development, Girdin expression is temporally and spatially restricted (16). At embryonic day (E) 10.5, Girdin mRNA was detected in the branchial arches, nasal processes, limbs, somites and dorsal root ganglia. At E11.5-E12.5, its expression persists at these sites and was also detected in the fore-, mid-, and hindbrain, and the interdigital mesenchyme of the limbs as well as in the developing eye.

3. 4. dGirdin is necessary for viability of Drosophila

In order to investigate the function of dGirdin in living flies, transgenic flies carrying UAS-dGirdin-IR were crossed with Actin5C-GAL4 driver lines to knockdown dGirdin in all fly tissues and the progeny flies exhibited late pupal lethality(10). Western blot analysis using anti-dGirdin antibodies revealed preferential knockdown of dGirdin PA by dGirdin-dsRNA in whole bodies, although it was designed to knockdown both mRNAs. Therefore it is suggested that at least dGirdin PA is necessary for viability of Drosophila. In accordance with this, the dGirdin mutants also show homozygous lethal phenotype, although the lethal phase is not precisely determined yet(10).

The Girdin deficient mice did not show apparent gross abnormalities at birth, but they displayed weight loss after postnatal day 7-8 (P7-8) and died by P25 without any serious pathological changes(12, 25). Therefore mouse Girdin is also necessary for viability of mouse. Detailed studies with Girdin-knockout mice revealed that Akt-mediated phosphorylation of Girdin promotes vascular endothelial growth factor (VEGF)-mediated postneonatal angiogenesis(12). Moreover Girdin-knockout mice show severe defects in the cytoarchitecture of the denate gyrus of the hippocampus that is known to develop postnatally(25). The defect is due to abnormal migration and/or positioning of newborn neurons in the dentate gyrus that is regulated by the interaction of Girdin with Disrupted-In-Schizophrenia 1 (DISC 1), a susceptibility gene for major mental illness including schizophrenia(26, 27). It is noted that the data suggest the interesting role of Girdin in pathoetiology of these psychiatric diseases.

3. 5. dGirdin is required to control appropriate cell size in Drosophila wings

The Drosophila wing is an appropriate tissue to investigate cell size control. Since each wing cell is known to produce one hair during development, one can easily measure cell density in the defined wing area by simply counting the hairs(28). Knockdown of dGirdin using an en-GAL4 driver line which drives expression of dGirdin-dsRNA in cells in the posterior compartment of the wing resulted in a reduction of posterior wing area (Figure 2) (10). Specific reduction of both dGirdin PA and PB in the posterior compartment of wing imaginal discs was confirmed by immunostaining with the anti-dGirdin antibody recognizing both dGirdin PA and PB(10). To examine whether the reduction in posterior wing area was caused by a decrease in cell size or a loss of cell number, we measured cell density in posterior wing areas in each fly by counting the hairs in defined areas, as each wing cell is known to produce one hair during development. The results revealed posterior wing compartments in which dGirdin was knocked down to exhibit higher cell density than controls and that this effect correlates with the copy number of the UAS-dGirdin-IR transgene. The data thus indicate that reduction in the posterior wing area induced by knockdown of dGirdin is due to decrease in cell size (10).

To exclude off-target effects of dGirdin-knockdown experiments, we examined whether the reduction in posterior wing area observed upon dGirdin-knockdown was sensitive to mutation in the dGirdin gene. On the dGirdin mutant background, reduction of posterior region of the dGirdin knockdown wings was further enhanced and cell density increased(10). The results indicate that the wing phenotype induced by dGirdin knockdown is indeed due to reduction of dGirdin.

3. 6. dGirdin is necessary for actin filament accumulation and may function downstream of the Akt

Human Girdin has been identified as a substrate of Akt functioning under the control of Akt phosphorylation(9). To determine whether dGirdin functions in a similar manner, we examined genetic interactions between dGirdin and Akt in Drosophila by observing the effects of Akt mutation on wing phenotype induced by knockdown of dGirdin(10). Half reduction of the Akt gene dose strongly enhanced the wing phenotype, with dramatic reduction in cell size in the wing. To further confirm in vivo roles of dGirdin under Akt influence, we examined the effect of Akt-overexpression on the wing phenotype (10). Overexpression of Akt in Drosophila wing using the en-GAL4 driver enlarged the posterior wing compartment area. In addition, the cell density was rather decreased, consistent with the widely known function of Akt in upregulating cell growth in a cell-autonomous manner. However, when dGirdin was knocked down in posterior compartments in which Akt was overexpressed, the elevation of cell size was suppressed with rescue to the normal level (Figure 2). These observations, taken together, suggest that dGirdin functions downstream of Akt in the control of cell size of the wing (Figure 3).

Mammalian Girdin is reported to be an actin-binding protein, which functions under the control of Akt(9). In human fibroblast cells, Girdin was shown to be essential for organization of the actin cytoskeleton, actin stress fibers being disrupted in Girdin-knockdown cells with loss of shape and formation of rugged boundaries(9). In wing imaginal discs from flies in which dGirdin was specifically knocked down in the posterior region by using en-GAL4 driver, immunofluorescent staining with polyclonal anti-dGirdin antibody showed that the level of dGirdin was considerably reduced in the posterior region. When actin filaments were visualized by staining with phalloidin, the region in which dGirdin was knocked down exhibited low accumulation(10). These results indicate that dGirdin is essential for the organization of the actin filaments in Drosophila as with its human counterpart (Figure 3).

3. 7. Role of Girdin in progression of human cancers

It is well known that aberrant Akt signaling is involved in the initiation and progression of human cancers (29-34). Therefore it is likely that the Akt/Girdin pathway also contributes to the malignant behavior of cancer cells. Many case studies revealed that Girdin is expressed in a wide variety of cancer cell lines and tissues including epithelium-derived and endothelium-derived malignant tumors, suggesting that Girdin plays important roles in cancer development and/or progression(11, 12, 35, 36).

Many cancer cells possess the ability to invade and metastasize to adjacent and distant tissues. The cytoskeleton is the force-generating apparatus that moves cells from one place to another and actin filaments regulate many aspects of dynamic cell motility(37). A number of actin-binding proteins and Rho GTPases, which are controlled by a variety of intercellular signaling such as the PI3K/Akt pathway, play crucial roles in regulating actin reorganization(38, 39). Many lines of evidence indicates that the PI3K/Akt signaling pathway also regulates the migration of cancer cells through several mechanisms such as phosphorylation of Girdin at the leading edge of migrating cells(11). In quiescent cells without growth factors, Girdin primarily localizes along actin stress fibers(15). However in migrating cells, Girdin preferentially localizes to the actin meshwork structure of the lamellipodia at the leading edge(9, 11, 12). In response to migratory cues such as growth factors, the phosphorylation of Girdin by Akt occurs at the leading edge, which is required for directional cell migration that in case of cancer cells ultimately leads to invasion and metastasis(13).

Angiogenesis is necessary for tumorigenesis including metastasis and therefore inhibiting angiogenesis has advantages as a cancer treatment strategy (40, 41). Among various factors involved in angiogenesis, members of the vascular endothelial growth factor (VEGF) and angiopoietin families have predominant roles(40, 42). Girdin is highly expressed in human umbilical vein endothelial cells and its phosphorylation by Akt regulates VEGF/Akt-dependent angiogenesis in vitro and in vivo(12). Phenotypic analysis of Girdin-knockout mice showed that Girdin is dispensable for embryonic vascular development but is required for postnatal vascular formation(12). Thus Girdin, although vital for cancer progression and postnatal vascular remodeling, is dispensable for cell migratory events during embryonic development. These findings suggest that Girdin and its interacting proteins are potential pharmaceutical targets for cancer therapies and tumor angiogenesis.

3. 7. Drosophila models for tumor metastasis and angiogenesis

Mutations in several tumor suppressor genes in Drosophila, including lethal(2)giant larvae (lgl), discs large (dlg) and scribble (scrib), are well known to promote tissue overgrowth(43-45). These proteins are widely expressed and normally act together to regulate apical-basal polarity in epithelial cells. Although the mechanism by which these proteins control polarity is not entirely clear at the molecular level, they are proposed to work as scaffolding proteins that control the segregation of membrane proteins to distinct domains of the cell (46). In addition, they affect downstream signaling events such as the activation of Rho GTPases. By taking advantage of mutations in these tumor suppressor genes, two different systems were developed to generate marked tumors in vivo and then follow tumor cells that have moved to other places (46).

In a first system, tumor cells expressing a reporter gene such as lacZ are dissected from lgl or dlg mutant larvae and then transplanted into the abdomens of adult hosts(44). Later the marked cells can be identified even in distant places to the site of injection by simply immunostaining with anti-lacZ antibody (46). Since invasive cells are able to cross multiple cell layers and basement membranes during their spread, this Drosophila model could be used to genetically identify other genes required for these events (47). A second system took advantage of the sophisticated genetic tricks in Drosophila to generate GFP-marked mutant clones expressing either a gain-of-function allele of Ras, RasV12, or homozygous for loss-of-function mutations in scrib while simultaneously altering additional genetic pathways (48, 49). The mutations in scrib, in the RasV12 background results in tumor cells to invade neighboring cells. It would be interesting to examine role of dGirdin in these metastasis systems in Drosophila.

Drosophila developed a tube-like heart and an open circulatory system for blood cells and there are no blood or lymphatic vessels. However, the development of the tracheal system in Drosophila very likely represents a model for angiogenesis in human (50, 51). In Drosophila less than 100 cells in each half-segment organize themselves into tubes. Cells at the tips of the tubes grow out into peripheral tissues to form fine branches as they ramify along stereotyped trajectories. Branchless, a FGF-like protein plays a major role in patterning the branches and guiding their outgrowth. Branchless binds and activates a receptor tyrosine kinase Breathless (51, 52). It should be noted that dGirdin is highly expressed in the tracheal system and may play a role in development of the tracheal system in Drosophila.

4. SUMMARY AND PERSPECTIVES

A novel Girdin-like protein has been identified in Drosophila, which has two isoforms, dGirdin PA and dGirdin PB. Knockdown of dGirdin in the Drosophila wing imaginal disc cells resulted in reduction of cell size. In the wing disc, dGirdin was also required for accumulation of actin filaments. Furthermore, these effects were enhanced by half reduction of the Akt gene dose. From these in vivo analyses, we conclude that dGirdin is required for actin organization and regulation of appropriate cell size under control of the Akt signaling pathway (Figure 3). Many lines of evidence indicate that mammalian Girdin plays important roles in cancer progression and angiogenesis(13). An important observation is that Girdin is dispensable for cell migratory events during mouse embryonic development, although it is required for cancer progression and postnatal vascular remodeling. These findings suggest that Girdin and its interacting proteins are potential pharmaceutical targets for cancer therapies.

Drosophila is becoming a powerful model where many aspects of the tumorigenesis can be genetically recapitulated (53). In general Drosophila has the practical advantages of being small, highly fertile and having a short generation time. These characteristics allow large-scale genetic screens and high-throughput screen of candidate drugs for therapy, to be performed in a relatively short period of time and at low cost (54, 55). dGirdin-knockdown and dGirdin-overexpressing flies showed a characteristic wing phenotype. These transgenic flies should prove to be useful tools for genetically identifying novel targets of dGirdin and its positive or negative regulators in Drosophila. Human counterparts of these genetic interactants with the dGirdin gene could be potential pharmaceutical targets for cancer therapies and tumor angiogenesis in which human Girdin is involved. In addition these transgenic flies would be useful to screen various chemicals and natural substances that could modify the dGirdin activity. This screen could be a first step to identify candidate drugs for therapy of human diseases including cancer in which human Girdin is involved.

5. ACKNOWLEDGEMENTS

This work was partially supported by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

6. REFERENCES

1. R. S. S. Fraser, and P. Nurse. Novel cell cycle control of RNA synthesis in yeasts. Nature 27 726-730 (1978)
doi:10.1038/271726a0
PMid:625340

2. J. Montagne, M. J. Stewart, H. Stocker, E. Hafen, S. C. Kozma, and G. Thomas. Drosophila S6 kinase: a regulator of cell size. Science 285 2126-2129 (1999)
doi:10.1126/science.285.5436.2126
PMid:10497130

3. D. P. Brazil, J. Park, and B. A. Hemmings. PKB binding proteins: Getting in on the Akt. Cell 111 293-303 (2002)
doi:10.1016/S0092-8674(02)01083-8

4. S. R. Datta, A. Brunet, and M. E. Greenberg. Cellular survival: a play in three Akts. Genes Dev. 13 2905-2927 (1999)
doi:10.1101/gad.13.22.2905

5. I. Vivanco, and C. L. Sawyers. The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nat. Rev. Cancer 2 489-501 (2002)
doi:10.1038/nrc839
PMid:12094235

6. S. Merlot, and R. A. Firtel. Leading the way: directional sensing through phosphatidylinositol 3-kinase and other signaling pathway. J. Cell Sci. 116 3471-3478 (2003)
doi:10.1242/jcs.00703
PMid:12893811

7. S. R. Datta, H. Dudek, X. Tao, S. Masters, H. Fu, Y. Gotoh, and M. E. Greenberg. Akt phospholylation of Bad couples survival signals to cell-intrinsic death machinery. Cell 91 231-241 (1997)
doi:10.1016/S0092-8674(00)80405-5

8. B. D. Manning, and L. C. Cantley. AKT/PKB signaling:navigating downstream. Cell 129 1261-1274 (2007)
doi:10.1016/j.cell.2007.06.009
PMid:17604717    PMCid:2756685

9. A. Enomoto, H. Murakami, N. Asai, N. Morone, T. Watanabe, K. Kawai, Y. Murakumo, J. Usukura, K. Kaibuchi, and M. Takahashi. Akt/PKB regulates actin organization and cell motility via Girdin/APE. Dev. Cell 9 389-402 (2005)
doi:10.1016/j.devcel.2005.08.001
PMid:16139227

10. A. Puseenam, Y. Yoshioka, R. Nagai, R. Hashimoto, O. Suyari, M. Itoh, A. Enomoto, M. Takahashi, and M. Yamaguchi. A novel Drosophila Girdin-like protein is involved in Akt pathway control of cell size. Exp. Cell Res. 315 3370-3380 (2009)
doi:10.1016/j.yexcr.2009.06.019
PMid:19560458

11. P. Jiang, A. Enomoto, M. Jijiwa, T. Kato, T. Hasegawa, M. Ishida, S. T., N. Asai, Y. Murakumo, and M. Takahashi. An actin-binding protein Girdin regulates the motility of breast cancer cells. Cancer Res. 68 1310-1318 (2008)
doi:10.1158/0008-5472.CAN-07-5111
PMid:18316593

12. T. Kitamura, N. Asai, A. Enomoto, K. Maeda, T. Kato, M. Ishida, P. Jiang, T. Watanabe, J. Usukura, T. Kondo, F. Constantini, T. Murohara, and M. Takahashi. Regulation of VEGF-mediated angiogenesis by the Akt/PKB substrate Girdin. Nature Cell Biol. 10 329-337 (2008)
doi:10.1038/ncb1695
PMid:18264090

13. L. Weng, A. Enomoto, M. Ishida-Takagishi, N. Asai, and M. Takahashi. Girdin for migrating cues: roles of the Akt substrate Girdin in cancer progression and angiogenesis. Cancer Sci. in press (2010)
doi:10.1111/j.1349-7006.2010.01487.x
PMid:20132219

14. M. Anai, N. Shojima, H. Katagiri, T. Ogihara, H. Sakoda, Y. Onishi, H. Ono, M. Fujishiro, Y. Fukushima, and N. Horike. A novel protein kinase B (PKB)/AKT-binding protein enhances PKB kinase activity and regulates DNA synthesis. J. Biol. Chem. 280 18525-18535 (2005)
doi:10.1074/jbc.M500586200
PMid:15753085

15. H. Le-Niculescu, I. Niesman, T. Fischer, L. DeVries, and M. G. Farquhar. Identification and characterization of GIV, a novel Gα i/s-interacting protein found on COPI, endoplasmic reticulum-Golgi transport vesicles. J. Biol. Chem. 280 22012-22020 (2005)
doi:10.1074/jbc.M501833200
PMid:15749703

16. F. Simpson, S. Martin, T. M. Evans, M. Kerr, D. E. James, R. G. Parton, R. D. Teasdale, and C. Wicking. A novel Hook-related protein family and the characterization of Hook-related protein 1. Traffic 6 442-458 (2005)
doi:10.1111/j.1600-0854.2005.00289.x
PMid:15882442

17. G. J. Praefcke, and H. T. McMahon. The dynamin superfamily:universal membrane tubulation and fission molecules? Nat. Rev. Mol. Cell Biol. 5 133-147 (2004)
doi:10.1038/nrm1313
PMid:15040446

18. A. Oshita, S. Kishida, H. Kobayashi, T. Michiue, T. Asahara, M. Asashima, and A. Kikuchi. Identification and characterization of a novel Dvl-binding protein that suppresses Wnt signalling pathway. Genes Cells 8 1005-1017 (2003)
doi:10.1111/j.1365-2443.2003.00692.x
PMid:14750955

19. N. Hay. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8 179-183 (2005)
doi:10.1016/j.ccr.2005.08.008
PMid:16169463

20. C. J. Potter, L. G. Pedraza, and T. Xu. Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell. Biol. 4 658-665 (2002)
doi:10.1038/ncb840
PMid:12172554

21. K. M. Hennig, J. Colombani, and T. P. Neufeld. TOR coordinates bulk and targeted endocytosis in the Drosophila melanogaster fat body to regulate cell growth. J. Cell Biol. 173 963-974 (2006)
doi:10.1083/jcb.200511140
PMid:16785324    PMCid:1950482

22. A. L. Edinger, and C. B. Thompson. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol. Biol. Cell 13 2276-2288 (2002)
doi:10.1091/mbc.01-12-0584
PMid:12134068    PMCid:117312

23. D. C. Fingar, S. Salama, C. Tsou, E. Harlow, and J. Blenis. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 16 1472-1487 (2002)
doi:10.1101/gad.995802

24. T. Radimerski, J. Montagne, F. Rintelen, H. Stocker, J. van der Kaay, C. P. Downes, E. Hafen, and G. Thomas. dS6K-regulated cell growth is dPKB/dPI(3)K-independent, but requires dPDK1. Nat. Cell Biol. 4 251-255 (2002)
doi:10.1038/ncb763
PMid:11862217

25. A. Enomoto, N. Asai, T. Namba, Y. Wang, T. Kato, M. Tanaka, H. Tatsumi, S. Taya, D. Tsuboi, K. Kuroda, N. Kaneko, K. Sawamoto, R. Miyamoto, M. Jijiwa, Y. Murakumo, M. Sokabe, T. Seki, K. Kaibuchi, and M. Takahishi. Roles of disrupted-in-schizophrenia 1-interacting protein girdin in postnatal development of the dentate gyrus. Neuron 63 774-787 (2009)
doi:10.1016/j.neuron.2009.08.015
PMid:19778507

26. J. K. Millar, J. C. Wilson-Annan, S. Anderson, S. Christie, M. S. Tayler, C. A. Semple, R. S. Devon, D. M. St. Clair, W. J. Muir, D. H. Blackwood, and D. J. Porteous. Disruption of two movel genes by a translocation co-segregating with schizophrenia. Hum. Mol. Genet. 9 1415-1423 (2000)
doi:10.1093/hmg/9.9.1415
PMid:10814723

27. J. Y. Kim, X. Duan, C. Y. Liu, M. H. Jang, J. U. Guo, N. Pow-anpongkul, E. Kang, H. Song, and G. L. Ming. DISC1 regulates new neuron development. Neuron 63 711-713 (2009)

28. C. A. Meyer, H. W. Jacobs, S. A. Datar, W. Du, B. A. Edgar, and C. F. Lehner. Drosophila Cdk4 is required for normal growth and is dispensable for cell cycle progression. EMBO. J. 19 4533-4542 (2000)
doi:10.1093/emboj/19.17.4533
PMid:10970847    PMCid:302073

29. J. Luo, B. D. Manning, and L. C. Cantley. Targeting the PI3K-Akt pathway in human cancer: Rational and promise. Cancer Cell 4 257-262 (2003)
doi:10.1016/S1535-6108(03)00248-4

30. H. G. Wendel, E. De Stanchina, J. S. Fridman, A. Malina, S. Ray, S. Kogan, C. Cordon-Cardo, J. Pelletier, and S. W. Lowe. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428 267-269 (2004)
doi:10.1038/nature02369
PMid:15029198

31. Y. Samuels, and K. Erickson. Oncogenic PI3K and its role in cancer. Curr. Opin. Oncol. 18 77-82 (2006)
doi:10.1097/01.cco.0000198021.99347.b9
PMid:16357568

32. B. T. Hennessy, D. L. Smith, P. T. Ram, Y. Lu, and G. B. Mills. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4 988-1004 (2005)
doi:10.1038/nrd1902
PMid:16341064

33. E. Hernando, E. Charytonowicz, M. E. Dudas, S. Menendez, I. Matushansky, J. Mills, N. D. Socci, N. Behrendt, L. Ma, R. G. Maki, P. P. Pandolfi, and C. Cordon-Cardo. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat. Med. 13 748-753 (2007)
doi:10.1038/nm1560
PMid:17496901

34. J. Brognard, A. S. Clark, Y. Ni, and P. K. Dennis. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 61 3986-3997 (2001)
PMid:11358816

35. P. Ghosh, M. Garcia-Marcos, S. J. Bornheimer, and M. G. Farquhar. Activation of Gai3 triggers cell migration via regulation of GIV. J. Cell Biol. 182 381-393 (2008)
doi:10.1083/jcb.200712066
PMid:18663145    PMCid:2483528

36. B. Zhang, F. Gu, C. She, H. Guo, W. Li, R. Niu, L. Fu, N. Zhang, and Y. Ma. Reduction of Akt2 inhibits migration and invasion of glioma cells. Int. J. Cancer 125 585-595 (2009)
doi:10.1002/ijc.24314
PMid:19330838

37. T. B. Pollard, and G. G. Borisy. Cellular motility driven by assembly and disassembly of actin filaments. Cell 112 453-465 (2003)
doi:10.1016/S0092-8674(03)00120-X

38. A. J. Ridley, M. A. Schwartz, K. Burridge, R. A. Firtel, M. H. Ginsberg, G. Borisy, J. T. Parsons, and A. R. Horwitz. Cell migration: Integrating signals from front to back. Science 302 1704-1709 (2003)
doi:10.1126/science.1092053
PMid:14657486

39. S. Etienne-Manneville, and A. Hall. Rho GTPases in cell biology. Nature 420 629-635 (2002)
doi:10.1038/nature01148
PMid:12478284

40. P. Carmeliet, and R. K. Jain. Angiogenesis in cancer and other diseases. Nature 407 249-257 (2000)
doi:10.1038/35025220
PMid:11001068

41. N. Ferrara, and R. S. Kerbel. Angiogenesis as a therapeutic target. Nature 438 967-974 (2005)
doi:10.1038/nature04483
PMid:16355214

42. L. Coultas, K. Chawengsaksophak, and J. Rossant. Endothelial cells and VEGF in vascular development. Nature 438 937-945 (2005)
doi:10.1038/nature04479
PMid:16355211

43. D. Bilder. Epithelial polarity and proliferation control: links from the Drosophila neoplastic tumor suppressors. Genes Dev. 28 1909-1925 (2004)
doi:10.1101/gad.1211604

44. F. Froldi, M. Ziosi, G. Tomba, F. Parisi, F. Garoia, A. Pession, and D. Grifoni. Drosophila lethal giant larvae neoplastic mutant as a genetic tool for cancer modeling. Current Genomics 9 147-154 (2008)
doi:10.2174/138920208784340786
PMid:19440511    PMCid:2679652

45. P. O. Humbert, L. E. Dow, and S. M. Russell. The Scribble and Par complexes in polarity and migration: friends or foes? Trends Cell Biol. 16 622-630 (2006)
doi:10.1016/j.tcb.2006.10.005
PMid:17067797

46. A. C.-C. Jang, M. Starz-Gaiano, and D. J. Montell. Modeling migration and metastasis in Drosophila. J. Mammary Gland Biol. Neoplasia 12 103-114 (2007)
doi:10.1007/s10911-007-9042-8
PMid:17549611

47. E. C. Woodhouse, A. Fisher, R. W. Bandle, B. Bryant-Greenwood, L. Charboneau, E. F. Petricoin, and L. A. Liotta. Drosophila screening model for metastasis: Semaphorin 5c is required for l(2)gl cancer phenotype. Proc. Natl. Acad. Sci. USA 100 11463-11468 (2003)
doi:10.1073/pnas.2031202100
PMid:14500904    PMCid:208780

48. A. M. Brumby, and H. E. Richardson. Using Drosophila melanogaster to map human cancer pathways. Nat. Rev. Cancer 5 626-639 (2005)
doi:10.1038/nrc1671
PMid:16034367

49. R. A. Pagliarini, and T. Xu. A genetic screen in Drosophila for metastasis behavior. Science 302 1227-1231 (2003)
doi:10.1126/science.1088474
PMid:14551319

50. R. J. Metzger, and M. A. Krasnow. Genetic control of branching morphogenesis. Science 284 1635-1639 (1999)
doi:10.1126/science.284.5420.1635
PMid:10383344

51. B. E. Kerman, A. M. Cheshire, and D. J. Andrew. From fate to function: the Drosophila trachea and salivary gland as models for tubulogenesis. Differentiation 74 326-348 (2006)
doi:10.1111/j.1432-0436.2006.00095.x
PMid:16916373

52. M. Affolter, S. Bellusci, N. Itoh, B. Shilo, J. P. Thiery, and Z. Werb. Tube or not tube: remodeling epithelial tissues by branching morphogenesis. Dev. Cell 4 11-18 (2003)
doi:10.1016/S1534-5807(02)00410-0

53. K. J. Venken, and H. J. Bellen. Emerging technologies for gene manipulation in Drosophila melanogaster. Nat. Rev. Genet. 6 167-178 (2005)
doi:10.1038/nrg1553
PMid:15738961

54. M. Leyssen, and B. Hassan. A fruitfly's guide to keeping the brain wired. EMBO reports 8 46-50 (2007)
doi:10.1038/sj.embor.7400869
PMid:17203102    PMCid:1796755

55. E. Bier. Drosophila, the golden bug, emerges as a tool for human genetics. Nat. Rev. Genet. 6 9-23 (2005)
doi:10.1038/nrg1503
PMid:15630418

Abbreviations: Girdin, griders of actin filaments; PKB, Protein Kinase B; Daple, Dishevelled-associating protein with a high frequency of leucine residues; PIP3, phosphatidylinositol-3,4,5-triphosphate; PI3K , phosphatidylinositol-3-kinase; TOR, targeting rapamycin; VEGF, vascular endothelial growth factor; lgl, lethal(2)giant larvae; dlg, discs large; scrib, scribble

Key Words: Cell size control, Drosophila, Girdin, Akt/PKB, Metastasis, Angiogenesis, Actin, Review

Send correspondence to: Masamitsu Yamaguchi, Address: Department of Applied Biology, Kyoto Institute of Technology, Matsugasaki, Sakyo-ku, Kyoto 606-8585, Japan, Tel: 81-75-724-7781, Fax: 81-75-724-7799, E-mail:myamaguc@kit.ac.jp